Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 7/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.64 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769292 | 1.00 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL24575640 | 0.90 | P2RY6 (0.67) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL4575896 | 0.90 | P2RY2 (0.76) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL10959520 | 0.89 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL20769289 | 0.89 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL600248 | 0.89 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL20769287 | 0.89 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056722 | 0.89 | P2RY6 (0.66) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL13834782 | 0.89 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL8091045 | 0.89 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024027809-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2024-02-08 | — | — | WO | claimed |
| WO-2023169548-A1 | LPA INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-09-14 | — | — | WO | claimed |
| JP-2007501615-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654362-A2 | 5'-AND 3'-CAPPED APTAMERS AND USES THEREFOR | EYETECH PHARMACEUTICALS, INC. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | claimed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2024088190-A1 | RNA INHIBITOR FOR INHIBITING LPA GENE EXPRESSION AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024027809-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2024-02-08 | — | — | WO | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| WO-2023169548-A1 | LPA INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-09-14 | — | — | WO | disclosed |
| US-20230110095-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | HANGZHOU HYGIEIA PHARMACEUTICAL CO., LTD. (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230013636-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES WITH FIBROSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-19 | — | — | US | disclosed |
| US-20050260153-A1 | Facilitation of iontophoresis using charged moieties | OLDTECH, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050260651-A1 | Enhanced biologically active conjugates | OLDTECH, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110489-A2 | NUCLEIC ACID APTAMERS CONJUGATED TO HIGH MOLECULAR WEIGHT STERIC GROUPS | (OSI) EYETECH, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050096257-A1 | Administering platelet derived growth factor antagonist and endothelial growth factor antagonist | OPHTHOTECH CORPORATION | 2005-05-05 | — | — | US | disclosed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005020972-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS | (OSI) EYETECH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | P2RY6 4473/4885P2RY2 4752/4885P2RY4 4709/4885 |
| US-20230110095-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | P2RY6 4473/4885P2RY2 4752/4885P2RY4 4709/4885 |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | P2RY6 1295/4885P2RY2 1820/4885P2RY4 984/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | P2RY6 4537/4885P2RY2 4804/4885P2RY4 4744/4885 |
| US-20050260153-A1 | Facilitation of iontophoresis using charged moieties | ANXA11, SLC7A1, TRPC6 | P2RY6 218/4885P2RY2 307/4885P2RY4 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.